UBS Group
SUPN icon

UBS Group’s Supernus Pharmaceuticals SUPN Stock Holding History

UBS Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8M Buy
209,124
+166,077
+386% +$8.46M ﹤0.01% 3240
2025
Q4 		$2.14M Sell
43,047
-497,076
-92% -$24.2M ﹤0.01% 4922
2025
Q3 		$25.8M Buy
540,123
+312,775
+138% +$12.6M ﹤0.01% 2284
2025
Q2 		$7.17M Sell
227,348
-22,968
-9% -$736K ﹤0.01% 3483
2025
Q1 		$8.2M Buy
250,316
+50,290
+25% +$1.78M ﹤0.01% 3262
2024
Q4 		$7.23M Buy
200,026
+91,168
+84% +$3.21M ﹤0.01% 3416
2024
Q3 		$3.39M Buy
108,858
+28,772
+36% +$898K ﹤0.01% 3456
2024
Q2 		$2.14M Buy
80,086
+15,542
+24% +$450K ﹤0.01% 3712
2024
Q1 		$2.2M Sell
64,544
-875
-1% -$26.1K ﹤0.01% 3848
2023
Q4 		$1.89M Buy
65,419
+46,390
+244% +$1.23M ﹤0.01% 3875
2023
Q3 		$525K Sell
19,029
-34,884
-65% -$1.06M ﹤0.01% 4605
2023
Q2 		$1.62M Buy
53,913
+14,278
+36% +$500K ﹤0.01% 3737
2023
Q1 		$1.44M Buy
39,635
+11,573
+41% +$445K ﹤0.01% 3765
2022
Q4 		$1M Buy
28,062
+20,517
+272% +$713K ﹤0.01% 4073
2022
Q3 		$256K Buy
7,545
+5,961
+376% +$194K ﹤0.01% 4881
2022
Q2 		$45K Sell
1,584
-82,180
-98% -$2.35M ﹤0.01% 6005
2022
Q1 		$2.71M Sell
83,764
-15,235
-15% -$467K ﹤0.01% 3139
2021
Q4 		$2.89M Buy
98,999
+95,951
+3,148% +$2.91M ﹤0.01% 3399
2021
Q3 		$81K Sell
3,048
-21,095
-87% -$566K ﹤0.01% 5979
2021
Q2 		$744K Sell
24,143
-151,006
-86% -$4.63M ﹤0.01% 4419
2021
Q1 		$4.58M Sell
175,149
-6,233
-3% -$174K ﹤0.01% 2706
2020
Q4 		$4.56M Buy
181,382
+164,612
+982% +$3.54M ﹤0.01% 2543
2020
Q3 		$350K Sell
16,770
-12,947
-44% -$294K ﹤0.01% 4436
2020
Q2 		$706K Sell
29,717
-11,111
-27% -$245K ﹤0.01% 3838
2020
Q1 		$734K Sell
40,828
-12,747
-24% -$268K ﹤0.01% 3629
2019
Q4 		$1.27M Buy
53,575
+10,012
+23% +$243K ﹤0.01% 3983
2019
Q3 		$4.49M Sell
43,563
-652,699
-94% -$19.3M ﹤0.01% 2489
2019
Q2 		$23M Buy
696,262
+19,911
+3% +$682K 0.01% 1124
2019
Q1 		$23.7M Buy
676,351
+325,468
+93% +$12.1M 0.01% 1044
2018
Q4 		$11.7M Buy
350,883
+28,143
+9% +$1.21M 0.01% 1455
2018
Q3 		$16.3M Buy
322,740
+293,120
+990% +$14.5M 0.01% 1367
2018
Q2 		$1.77M Buy
29,620
+15,274
+106% +$791K ﹤0.01% 3273
2018
Q1 		$657K Buy
14,346
+641
+5% +$26.7K ﹤0.01% 4023
2017
Q4 		$546K Sell
13,705
-30,817
-69% -$1.22M ﹤0.01% 4233
2017
Q3 		$1.78M Buy
44,522
+29,740
+201% +$1.29M ﹤0.01% 3225
2017
Q2 		$637K Sell
14,782
-158
-1% -$5.62K ﹤0.01% 3945
2017
Q1 		$468K Sell
14,940
-5,071
-25% -$136K ﹤0.01% 4085
2016
Q4 		$505K Sell
20,011
-7,678
-28% -$172K ﹤0.01% 4111
2016
Q3 		$684K Buy
27,689
+23,175
+513% +$525K ﹤0.01% 3691
2016
Q2 		$92K Buy
4,514
+32
+0.7% +$568 ﹤0.01% 5088
2016
Q1 		$68K Sell
4,482
-47,448
-91% -$619K ﹤0.01% 5265
2015
Q4 		$698K Buy
51,930
+1,701
+3% +$26.3K ﹤0.01% 3684
2015
Q3 		$705K Buy
50,229
+3,212
+7% +$59.7K ﹤0.01% 3641
2015
Q2 		$798K Buy
47,017
+2,393
+5% +$34.1K ﹤0.01% 3744
2015
Q1 		$540K Buy
44,624
+12,283
+38% +$116K ﹤0.01% 4078
2014
Q4 		$269K Buy
+32,341
New +$272K ﹤0.01% 4755

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's SUPN Position: Q1 2026 in Review

UBS Group increased its Supernus Pharmaceuticals (SUPN) stake by 386% in Q1 2026, buying an estimated $8.46M and bringing the position to 209,124 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

UBS Group first reported a position in SUPN in Q4 2014 and has held it in 46 quarters since. The position peaked at $25.8M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • UBS Group held 209,124 shares of Supernus Pharmaceuticals worth $10.8M as of Q1 2026.
  • UBS Group bought 166,077 Supernus Pharmaceuticals shares in Q1 2026, an estimated $8.46M.
  • Supernus Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3240 holding.
  • UBS Group first reported a position in Supernus Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Supernus Pharmaceuticals position peaked at $25.8M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.